HIMS
NVO
New deal, same pressure
Hims & Hers is doing the thing every ambitious healthcare app wants to do: go from “cool consumer brand” to “real healthcare platform.” The company is rolling out Benefits and tapping Novo Nordisk for GLP therapies in weight-loss care, which sounds a lot more grown-up than the usual wellness-software vibe.
Why the market cares
On paper, this is exactly the kind of move that can widen Hims' addressable market. More services, more prescription volume, more reasons for customers to stick around instead of bouncing after a one-off order like they’re leaving a shopping cart behind at checkout.
But there’s a catch, because there’s always a catch. Revenue is still growing, which is nice, but the article flags tightening margins and cash flow. Translation: Hims may be sprinting to scale while the treadmill keeps getting steeper.
The investor tug-of-war
So you’ve got two competing narratives here:
- Bull case: stronger growth engine, better positioning in weight-loss care, and a more credible partnership story.
- Bear case: growth is getting pricier, and investors have learned the hard way that “expansion” can be code for “we’re spending a lot to chase it.”
That’s why Hims can feel like a stock with a built-in drama machine. The business is getting bigger, but the market still wants proof it can get bigger without burning too much fuel.
Big picture: this looks less like a victory lap and more like a strategic bet that Hims can turn healthcare distribution into a moat before the margin math gets ugly.